(919) 237-4897 info@t3dtherapeutics.com

News + Events

Stay up to date with our latest news

John Ratliff Joins T3D Therapeutics’ Advisory Board

John Ratliff recently retired from Quintiles as President and Chief Operating Officer. He led Quintiles’ Global Services organization with it’s clinical research, commercial, consulting, lab operations and was a member of the company’s Board of Directors. John helped...

T3D Therapeutics Reports Successful Pre-IND Meeting with the FDA

T3D Therapeutics announced today that it had a successful Type B Pre-Investigational New Drug (“Pre-IND) meeting on April 1st with the US Food and Drug Administration’s Division of Neurology Products, for T3D-959, a novel nuclear receptor agonist for the treatment of...